SCHEMBL31663796

SCHEMBL31663796

Cc1ncnc(C)c1-c1cc(NC(=O)[C@@H]2C[C@H]2F)ccc1OC[C@H]1CCCCN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.41
JAK3 P52333 2/20 0.40
FPR3 P25089 1/20 0.39
FPR2 P25090 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 2/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
RAB9A P51151 1/20 0.38
ABL1 P00519 2/20 0.37
F2RL3 Q96RI0 2/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31663765 0.91 NPC1 (0.44) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663763 0.91 NPC1 (0.44) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663788 0.91 NPC1 (0.44) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663807 0.89 NPC1 (0.44) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663811 0.86 FPR3 (0.39) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663776 0.86 PTPN2 (0.44) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663784 0.84 ALOX5AP (0.38) JAK2JAK3FPR3FPR2MEN1
SCHEMBL31663806 0.83 HTR2A (0.40) JAK2JAK3NPC1RAB9A
SCHEMBL31663752 0.82 ALOX5AP (0.44) ALOX5APFEN1F2RL3
SCHEMBL29619014 0.81 NPC1 (0.42) FPR3FPR2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto HTR2C, HTR1A, HTR2A JAK2 1272/4885JAK3 2379/4885FPR3 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.